Compare SHOO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | VERA |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 1993 | 2021 |
| Metric | SHOO | VERA |
|---|---|---|
| Price | $36.53 | $43.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $42.75 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $2,362,727,000.00 | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $12.67 | N/A |
| P/E Ratio | $45.72 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $19.05 | $18.53 |
| 52 Week High | $46.88 | $56.05 |
| Indicator | SHOO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 45.55 |
| Support Level | $33.89 | $40.87 |
| Resistance Level | $46.88 | $45.51 |
| Average True Range (ATR) | 2.13 | 2.26 |
| MACD | -1.16 | -0.50 |
| Stochastic Oscillator | 20.63 | 33.45 |
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.